Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

Michael P. Pender(The University of Queensland), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Meenakshi Raj(Royal Brisbane and Women's Hospital), Peter A. Csurhes(The University of Queensland), Alan Coulthard(Mental Health Research Institute), Scott R. Burrows(QIMR Berghofer Medical Research Institute), Leone Beagley, Kaye D. Hooper(The University of Queensland), Corey Smith(QIMR Berghofer Medical Research Institute)
Multiple Sclerosis Journal
February 3, 2014
10.1177/1352458514521888
Cited by 88

Related Papers

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
|New England Journal of Medicine|2018|856
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235